NEW YORK (GenomeWeb News) – Hybrigenics has received €400,000 ($510.4 million) to screen inhibitors of protein interaction under a collaboration with the Masterswitch European union research project.
Hybrigenics will use its protein interaction technologies and expertise in the field of chronic inflammatory diseases, the Paris-based firm said today. It will develop a high-throughput assay and screen its library of 100,000 compounds and its collection of around 2,000 natural substances. The goal is to identify small-molecule inhibitors of a therapeutically relevant protein interaction, said Hybrigenics.
The firm will receive the funding over the first two years of a five-year collaboration.
The Masterswitch project is part of the EU's 7th Framework Programme and includes a consortia of 16 participants. The primary objective of the project is to develop new treatments for chronic inflammatory diseases.